Q-omics provides the consensus-scored SRP14P3 profile across patient tissues and cancer cell-line models. SRP14P3 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, SRP14P3 is differentially expressed in 6, with the highest sampling consensus in COAD. Additionally, SRP14P3 RNA expression shows 13,107 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UVM, COAD, and GBM as cancer lineages where SRP14P3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SRP14P3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SRP14P3 survival associations across molecular data types. SRP14P3 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SRP14P3 RNA expression–survival associations across cancer types. High SRP14P3 expression shows unfavorable associations in UVM, LIHC and KIRP, but favorable associations in STAD, LUAD and LAML. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .006). Together, the overview and detailed table identify UVM as the clearest survival context for SRP14P3 RNA expression.
This table summarizes SRP14P3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for SRP14P3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SRP14P3 shows lower tumor expression in ESCA, LUAD and KIRC and higher tumor expression in COAD, BRCA and THCA. The COAD box plot shows higher SRP14P3 RNA expression in tumor versus normal tissue (log2 FC = +0.286, t-test p < 0.001).
This table shows molecular features associated with SRP14P3 in patient tissues and cancer cell lines. In patient samples, SRP14P3 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
